Filing Flows › Maxcyte (MXCT) › Q1 2025
Maxcyte (MXCT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Maxcyte (MXCT) reported revenue of $10.4M for the first quarter 2025 (Q1 2025), -8% from a year earlier and +20% from the quarter before. Operating margin was -118.3%, net loss $10.3M (98.8% of revenue).
Maxcyte, Q1 2025: revenue $10.4M (-8% year over year), operating margin -118.3%, net loss $10.3M, operating cash flow −$14.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.4M | +20% | -8% |
| Operating profit | −$12.3M | — | — |
| Net earnings | −$10.3M | — | — |
| Operating cash flow | −$14.4M | — | — |
What changed
Revenue was $10.4M in Q1 2025, down 8% year over year and up 20% from the previous quarter. Product sales was the largest line at 51% of revenue. Licenses lost $1.1M year over year (down 19%), 114% of the total change.
Gross margin was 85.6%, down 2.0 points from a year earlier. Operating costs exceeded revenue by $12.3M, an operating margin of -118.3%. Operating expenses fell 5% while revenue fell 8%. The fastest-growing cost line was General & admin (+20%). The quarter ended with a net loss of $10.3M, narrower than the previous quarter's $10.6M loss.
Operating cash flow was −$14.4M. Non-cash charges added back $1.1M of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $8.3M. Capital expenditures of $653K exceeded it, leaving free cash flow of −$15.1M.
Questions
What was Maxcyte's revenue in the first quarter 2025?
Maxcyte (MXCT) reported revenue of $10.4M for the first quarter 2025 (Q1 2025), -8% from a year earlier and +20% from the quarter before.
Was Maxcyte profitable in the first quarter 2025?
Operating loss was $12.3M (-118.3% of revenue) and net loss $10.3M.
Source: Maxcyte 10-Q on SEC EDGAR.